Proteasome inhibitors are the drugs that block the proteasomes, a cellular component that breakdown proteins. The proteasome inhibitors are being studied in the treatment of multiple myeloma, cancer, inflammatory disorders, and autoimmune disorders. A breakthrough multiple myeloma treatment received approval 2003 for, Bortezomib, the first proteasome inhibitor, which is a reversible boronic acid inhibitor of the chymotrypsin-like activity of proteasome. Other proteasome inhibitors such as, ixazomib and delanzomib, are in the late stage of clinical development and are reversible boronic acid proteasome inhibitors.
PROTEASOME INHIBITORS THERAPEUTICS CANDIDATES UNDER DEVELOPMENT (2017)
There are many pharmaceutical companies that are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as combination therapies or as single agent therapies. They also allow the development of specific targeted therapies with better drug delivery. For instance, in Cellivery’s Technology Platform, protein transduction exploits the ability of specific basic-, amphipathic- and hydrophobic-cell penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Cellivery Therapeutics, Inc has developed hydrophobic cell penetrating peptide, named macromolecule transduction domains (MTD) to deliver biologically active peptides and proteins into a variety of cells and tissues.
As of October 2017, the proteasome inhibitors pipeline comprised of approximately 20 drug candidates in different stages of development.
Some of the key players developing drugs as proteasome inhibitors include Triphase Accelerator Corporation, Cantex Pharmaceuticals, Inc., Accuitis, Inc. and others.